Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

February 3, 2025

Study Completion Date

February 3, 2025

Conditions
Primary Sjögren's Syndrome
Interventions
BIOLOGICAL

Efgartigimod

Patients receiving efgartigimod infusions

Trial Locations (11)

4032

Debreceni Egyetem, Debrecen

8000

Vita Verum Medical Egeszsegugyi Szolgaltato Bt., Székesfehérvár

9000

Universitair Ziekenhuis Gent, Ghent

05 825

MCBK SC, Grodzisk Mazowiecki

30 363

Centrum Medyczne Plejady, Krakow

60-848

Clinical Research Center Spółka z ograniczoną odpowiedzialnością Medic-R Sp.k., Poznan

60 185

Centrum Medyczne Pratia Poznan, Skorzewo

00 874

MICS Centrum Medyczne Warszawa, Warsaw

02 665

Klinika Reuma Park Sp zoo Sp K, Warsaw

02637

Narodowy Instytut Geriatrii, Warsaw

50 088

FutureMeds sp zoo, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

argenx

INDUSTRY